First-pass metabolism is the share of an orally taken dose that is altered or removed during its first pass through the gut wall and liver, before it reaches general circulation.
Why it matters for logging
A label dose is not the same as the effective dose at tissue. Compounds with heavy first-pass loss can show large day-to-day variance because gut transit, meal acidity, and enzyme activity shift how much survives the first pass. Two log entries with identical labels can produce different experiences without any change in product or amount.
How route changes first-pass exposure
Routes that bypass the gut and liver avoid much of this loss.
- Sublingual and buccal routes can bypass some gut and liver first-pass loss.
- Transdermal and inhaled routes also bypass much first-pass loss, though they introduce other variables.
- Swallowed forms remain useful for compounds whose activity actually depends on hepatic conversion.
Interaction with food and other compounds
Food can change gut transit time and enzyme activity, which shifts how much of a dose is metabolized on the first pass. Other compounds taken in the same window can compete for the same enzymes and raise or lower effective exposure in ways the label cannot show. Reviewing interaction checks before stacking new oral compounds helps surface likely overlaps.
Relation to bioavailability
First-pass loss is one reason a high-purity capsule can still produce low bioavailability. Route and form changes can therefore change exposure even when the label amount is unchanged.
Practical action step
When a swallowed product feels different from another route or format at the same label amount, record the route difference before assuming a product quality issue.
Uncertainty and limits
- Hepatic enzyme activity varies by genetics, illness, and co-medication in ways no label can predict.
- Many first-pass estimates come from single-dose studies that may not match repeat exposure in real routines.
Cross-site references
How this appears in Unfair
Unfair uses first-pass class data to compare expected exposure when users switch route or form, and to flag when a route switch may change effective exposure even at the same label amount.
Clinical safety note
If a route change produces effects that feel disproportionate to the label, pause changes and review with a clinician before continuing.